231 related articles for article (PubMed ID: 30171023)
1. Vascular endothelial cell expression of JAK2
Guy A; Gourdou-Latyszenok V; Le Lay N; Peghaire C; Kilani B; Dias JV; Duplaa C; Renault MA; Denis C; Villeval JL; Boulaftali Y; Jandrot-Perrus M; Couffinhal T; James C
Haematologica; 2019 Jan; 104(1):70-81. PubMed ID: 30171023
[TBL] [Abstract][Full Text] [Related]
2. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
3. Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features.
Guadall A; Lesteven E; Letort G; Awan Toor S; Delord M; Pognant D; Brusson M; Verger E; Maslah N; Giraudier S; Larghero J; Vanneaux V; Chomienne C; El Nemer W; Cassinat B; Kiladjian JJ
Thromb Haemost; 2018 Sep; 118(9):1586-1599. PubMed ID: 30103245
[TBL] [Abstract][Full Text] [Related]
4. The JAK2 V617F mutation and thrombosis.
Austin SK; Lambert JR
Br J Haematol; 2008 Nov; 143(3):307-20. PubMed ID: 19004076
[TBL] [Abstract][Full Text] [Related]
5. The clonal hematopoiesis mutation Jak2
Molinaro R; Sellar RS; Vromman A; Sausen G; Folco E; Sukhova GK; McConke ME; Corbo C; Ebert BL; Libby P
Int J Cardiol; 2024 Aug; 409():132184. PubMed ID: 38759798
[TBL] [Abstract][Full Text] [Related]
6. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Hexner EO
Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
[TBL] [Abstract][Full Text] [Related]
7. The first report of a JAK2 V617F-positive myeloproliferative neoplasm with initial manifestation as a rare pampiniform venous plexus thrombosis and review of the literature.
Jacobs J; Sharma D; Vnencak-Jones C
J Thromb Thrombolysis; 2022 Jan; 53(1):213-217. PubMed ID: 34240279
[TBL] [Abstract][Full Text] [Related]
8. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
[TBL] [Abstract][Full Text] [Related]
9. JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.
Ar MC; Hatemi G; Ekizoğlu S; Bilgen H; Saçli S; Buyru AN; Soysal T; Ülkü B; Yazici H
Clin Appl Thromb Hemost; 2012 Jul; 18(4):421-6. PubMed ID: 22203033
[TBL] [Abstract][Full Text] [Related]
10. JAK2
Lin CH; Kaushansky K; Zhan H
Blood Cells Mol Dis; 2016 Nov; 62():42-48. PubMed ID: 27865175
[TBL] [Abstract][Full Text] [Related]
11. Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.
Reeves BN; Beckman JD
Curr Hematol Malig Rep; 2021 Jun; 16(3):304-313. PubMed ID: 33876389
[TBL] [Abstract][Full Text] [Related]
12. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
[TBL] [Abstract][Full Text] [Related]
13. Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in
Chen CC; You JY; Lung J; Huang CE; Chen YY; Leu YW; Ho HY; Li CP; Lu CH; Lee KD; Hsu CC; Gau JP
Haematologica; 2017 Mar; 102(3):509-518. PubMed ID: 28057739
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
15. Endothelial PPAR-γ protects against vascular thrombosis by downregulating P-selectin expression.
Jin H; Gebska MA; Blokhin IO; Wilson KM; Ketsawatsomkron P; Chauhan AK; Keen HL; Sigmund CD; Lentz SR
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):838-44. PubMed ID: 25675995
[TBL] [Abstract][Full Text] [Related]
16. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.
Amaru Calzada A; Pedrini O; Finazzi G; Leoni F; Mascagni P; Introna M; Rambaldi A; Golay J;
Exp Hematol; 2013 Mar; 41(3):253-60.e2. PubMed ID: 23111067
[TBL] [Abstract][Full Text] [Related]
17. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
18. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Wolach O; Sellar RS; Martinod K; Cherpokova D; McConkey M; Chappell RJ; Silver AJ; Adams D; Castellano CA; Schneider RK; Padera RF; DeAngelo DJ; Wadleigh M; Steensma DP; Galinsky I; Stone RM; Genovese G; McCarroll SA; Iliadou B; Hultman C; Neuberg D; Mullally A; Wagner DD; Ebert BL
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643232
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses.
McMahon C; Abu-Elmagd K; Bontempo FA; Kant JA; Swerdlow SH
Am J Clin Pathol; 2007 May; 127(5):736-43. PubMed ID: 17439832
[TBL] [Abstract][Full Text] [Related]
20. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
Horvat I; Boban A; Zadro R; Antolic MR; Serventi-Seiwerth R; Roncevic P; Radman I; Sertic D; Vodanovic M; Pulanic D; Basic-Kinda S; Durakovic N; Zupancic-Salek S; Vrhovac R; Aurer I; Nemet D; Labar B
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):53-63. PubMed ID: 30301673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]